Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04579380
Title Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Seagen Inc.

Advanced Solid Tumor

brain cancer

Her2-receptor negative breast cancer


Trastuzumab + Tucatinib

Fulvestrant + Trastuzumab + Tucatinib

Age Groups: senior | adult
Covered Countries USA | ITA | ESP | BEL

No variant requirements are available.